Premium
Dermatomyositis‐like syndrome and HMG‐CoA reductase inhibitor (statin) intake
Author(s) -
Vasconcelos Olavo M.,
Campbell William W.
Publication year - 2004
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20127
Subject(s) - discontinuation , medicine , dermatomyositis , statin , simvastatin , rash , myalgia , hmg coa reductase , population , myopathy , pathological , muscle weakness , weakness , physical therapy , endocrinology , reductase , surgery , biochemistry , chemistry , environmental health , enzyme
A patient developed an adult‐onset dermatomyositis‐like syndrome characterized by skin rash and progressive proximal muscle weakness concurrent with the intake of simvastatin. Despite discontinuation of the statin, symptoms progressed and required conventional steroid therapy for remission. The association between statins and the development of a musculocutaneous syndrome closely resembling dermatomyositis in susceptible subjects is poorly understood and has been reported rarely. The purpose of this report is to provide additional support for this pathological association. Since the population receiving statins is large and rapidly growing, caregivers are urged to be alert regarding the early recognition and proper care of the spectrum of neuromuscular complications linked to statin intake. Muscle Nerve, 2004